View Future GrowthChugai Pharmaceutical 過去の業績過去 基準チェック /66Chugai Pharmaceuticalは、平均年間8.3%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間10.7% 4.7%収益成長率で 成長しています。 Chugai Pharmaceuticalの自己資本利益率は23.2%であり、純利益率は35.1%です。主要情報8.33%収益成長率8.31%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率4.67%株主資本利益率23.25%ネット・マージン35.10%次回の業績アップデート27 Oct 2026最近の業績更新お知らせ • Oct 27+ 3 more updatesChugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Jan 29, 2026Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Jan 29, 2026お知らせ • Oct 18+ 3 more updatesChugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Jan 30, 2025Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results at 5:00 PM, Tokyo Standard Time on Jan 30, 2025お知らせ • Dec 07+ 2 more updatesChugai Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024Chugai Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results at 5:00 PM, Tokyo Standard Time on Oct 25, 2024お知らせ • Dec 06Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Feb 01, 2024Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2023 results at 5:00 PM, Tokyo Standard Time on Feb 01, 2024お知らせ • Nov 01Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on Feb 02, 2023Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2022 results at 5:00 PM, Tokyo Standard Time on Feb 02, 2023お知らせ • Oct 28+ 2 more updatesChugai Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Apr 27, 2023Chugai Pharmaceutical Co., Ltd. announced that they will report Q1, 2023 results on Apr 27, 2023すべての更新を表示Recent updatesお知らせ • 5hChugai Pharmaceutical Files For Additional Indication Of Enspryng For Prevention Of Relapse In MOG Antibody-Associated Disease In JapanChugai Pharmaceutical Co., Ltd. filed a regulatory application with the Ministry of Health, Labour and Welfare for an additional indication of 'prevention of relapse in MOG antibody-associated disease' for Enspryng [generic name: satralizumab (genetical recombination)], a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody created by Chugai. Enspryng received forerunner designation in 2023 as a treatment for the disease. If approved, Enspryng would become the first treatment covered by health insurance in Japan for the disease. This filing is based on results from METEOROID, a global phase III clinical study in adults and adolescents (aged 12-17 years) with MOGAD. Development in Japan is conducted by Chugai, and Japanese patients have participated in this study. Enspryng, created by Chugai, is a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody, which was the first product developed by applying Chugai's proprietary recycling antibody technology. Recycling antibody technology received 'The Imperial Invention Prize,' the highest honor of the Fiscal Year 2026 National Commendation for Invention. Enspryng is approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in approximately 90 countries, including Japan, the United States, and Europe. A global phase III clinical study is currently ongoing in autoimmune encephalitis (AIE). In addition, the U.S. Food and Drug Administration (FDA) has accepted the filing for thyroid eye disease (TED) and granted priority review. MOG antibody-associated disease (myelin oligodendrocyte glycoprotein antibody-associated disease, MOGAD) is an autoimmune disease involving demyelination by which a pathogenic autoantibody, an anti-MOG antibody, binds to MOG, which is expressed on the surface of the myelin sheath in the central nervous system. MOGAD causes inflammation of the optic nerves, spinal cord and brain, with symptoms such as visual impairment, loss of sensation, motor dysfunction and dysuria. Currently, no approved therapies exist for the prevention of relapse in MOGAD, and in about 80% of adult patients, the disease is chronic and characterized by a relapsing course with currently used therapies. The inflammatory cytokine IL-6 may play a role in the pathogenesis of MOGAD by promoting the production of autoantibodies and inducing inflammatory effects. The number of patients in Japan is estimated to be approximately 1,700.お知らせ • Mar 23Chugai Pharmaceutical Co., Ltd. Announces Discontinuation Of Development Of GYM329 (Emugrobart) In Spinal Muscular Atrophy And Facioscapulohumeral Muscular DystrophyChugai Pharmaceutical Co., Ltd. announced that Roche has decided to discontinue the clinical development of GYM329 (emugrobart), an investigational anti-latent myostatin sweeping antibody, for spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD). This decision follows a rigorous assessment of data from the Phase II/III MANATEE study (Part 1) in SMA and the Phase II MANOEUVRE study in FSHD. While emugrobart showed a favorable safety profile and target engagement by reducing mature myostatin, it did not translate into the intended functional outcomes. Specifically, muscle growth and exploratory functional efficacy were neither consistent nor robust enough across study participants to provide sufficient confidence for Phase III development in SMA and FSHD. Emugrobart was well tolerated across both studies, with no serious adverse events or treatment withdrawals. The discontinuation of these studies was not due to safety concerns. As the scientific rationale for continuing to investigate emugrobart in obesity remains strong, this decision does not impact the development of emugrobart in obesity. Obesity is a chronic metabolic disease with symptoms and underlying causes being fundamentally different from neuromuscular conditions like SMA and FSHD. In obesity, muscle quality is not primarily affected by a neurodegenerative (nerve-wasting) or myopathic (muscle-wasting) process and there is generally more myostatin for an anti-myostatin antibody to act on. Consequently, the Phase II development of emugrobart in obesity will continue as planned.お知らせ • Feb 24Sarepta Therapeutics, Inc. Announces Commercial Launch of ELEVIDYS in JapanSarepta Therapeutics, Inc. announced the commercial launch of ELEVIDYS (delandistrogene moxeparvovec) in Japan by Chugai Pharmaceutical Co. Ltd., following its reimbursement listing on Japan's National Health Insurance (NHI) price list. ELEVIDYS is the first gene therapy to be launched in Japan for Duchenne muscular dystrophy (DMD). In Japan, ELEVIDYS is available for ambulatory individuals with Duchenne ages 3-to less than 8-years-old, a deletion of any portion or the entirety of exon 8 and/or exon 9 in the DMD gene, and who are negative for anti-AAVrh74 antibodies. Chugai announced that ELEVIDYS has been launched in Japan following reimbursement listing, enabling access for eligible patients under the conditional and time limited approval granted by Japan's Ministry of Health, Labour and Welfare (MHLW) in May 2025. Chugai will be responsible for postmarketing clinical studies and all case postmarketing surveillance in Japan as part of the Roche Group collaboration to further evaluate long-term efficacy and safety. The approval in Japan was based on efficacy and safety data from the ELEVIDYS clinical development program, including results from the global Phase 3 EMBARK study. EMBARK evaluated ELEVIDYS in ambulatory boys with DMD and demonstrated clinically meaningful improvements in key motor function measures. ADVERSE REACTIONS: The most common adverse reactions (incidence 5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, thrombocytopenia, and troponin-I increased. Report negative side effects of prescription drugs to the FDA.お知らせ • Jan 29+ 3 more updatesChugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026.お知らせ • Oct 27+ 3 more updatesChugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Jan 29, 2026Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Jan 29, 2026お知らせ • Oct 25Chugai Pharmaceutical Co., Ltd. (TSE:4519) agreed to acquire Renalys Pharma for ¥31 billion.Chugai Pharmaceutical Co., Ltd. (TSE:4519) agreed to acquire Renalys Pharma for ¥31 billion on October 24, 2025. A cash consideration of ¥15 billion will be paid by Chugai Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd. will pay an earnout/contingent payment of ¥16 billion cash. As part of consideration, ¥31 billion is paid towards common equity of Renalys Pharma. The expected completion of the transaction is November 30, 2025.お知らせ • Feb 01Chugai Pharmaceutical Co., Ltd. Provides Guidance for the Financial Year Ending December 31, 2025Chugai Pharmaceutical Co., Ltd. provided consolidated non-audited earnings guidance for the financial year ending December 31, 2025. For the year, company expects revenues of JPY 1,190,000 million, Core operating profit of JPY 570,000 million, Core net income of JPY 410,000 million and Core earnings per share of JPY 250.00.お知らせ • Jan 31Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2025Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2025.お知らせ • Jan 16CHEPLAPHARM K.K. agreed to acquire the Japan business concerning the anti-cancer agent Tarceva® Tablets 25, 100, and 150 from Chugai Pharmaceutical Co., Ltd. (TSE:4519).CHEPLAPHARM K.K. agreed to acquire the Japan business concerning the anti-cancer agent Tarceva® Tablets 25, 100, and 150 from Chugai Pharmaceutical Co., Ltd. (TSE:4519) on January 14, 2025. Upon completion, CHEPLAPHARM group will solely market Tarceva after transferring assets related to Tarceva that are owned by Roche Group and Chugai Pharmaceutical Co., Ltd. (TSE:4519), including the marketing authorization and intellectual property rights (patents and trademarks, etc.). The transfer of the marketing authorization is scheduled to take place on April 1, 2025, and the sales transfer is scheduled to take place in June 2025.お知らせ • Oct 18+ 3 more updatesChugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Jan 30, 2025Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results at 5:00 PM, Tokyo Standard Time on Jan 30, 2025お知らせ • Feb 01+ 1 more updateChugai Pharmaceutical Co., Ltd. Provides Consolidated Non-Audited Earnings Guidance for the Financial Year 2024Chugai Pharmaceutical Co., Ltd. provided consolidated non-audited earnings guidance for the financial year 2024. For the year, company expects revenues of JPY 1,070,000 million, Core operating profit of JPY 460,000 million, Core net income of JPY 335,500 million and Core earnings per share of JPY 204.00.お知らせ • Dec 07+ 2 more updatesChugai Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024Chugai Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results at 5:00 PM, Tokyo Standard Time on Oct 25, 2024お知らせ • Dec 06Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Feb 01, 2024Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2023 results at 5:00 PM, Tokyo Standard Time on Feb 01, 2024お知らせ • Oct 26+ 1 more updateChugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Nine Months and Financial Year Ending December 31, 2023Chugai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the first nine months and financial year ending December 31, 2023. For the first nine months, the company expects core revenues of ¥837,555 million, Core operating profit of ¥340,537 million, Core net income of ¥250,298 million and Core earnings per share of ¥152.11.For the year, company expects core revenues of ¥1,070,000 million, Core operating profit of ¥415,000 million, Core net income of ¥306,000 million and Core earnings per share of ¥186.00.お知らせ • Feb 03Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Financial Year 2023Chugai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the financial year 2023. For the year, company expects revenues of ¥1,070,000 million, Core operating profit of ¥415,000 million, Core net income of ¥306,000 million and Core earnings per share of ¥186.00.お知らせ • Feb 02+ 1 more updateChugai Pharmaceutical Co., Ltd. Approves Dividend Fiscal Year Ended December 31, 2022, Effective March 31, 2023Chugai Pharmaceutical Co., Ltd. at its board meeting held on February 2, 2023 approved to distribute retained earnings with the record date being December 31, 2022 for the fiscal year ended December 31, 2022. Dividends per share is JPY 40.00. Total dividends are JPY 65,801 million. Effective date is March 31, 2023.お知らせ • Nov 01Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on Feb 02, 2023Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2022 results at 5:00 PM, Tokyo Standard Time on Feb 02, 2023お知らせ • Oct 28+ 2 more updatesChugai Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Apr 27, 2023Chugai Pharmaceutical Co., Ltd. announced that they will report Q1, 2023 results on Apr 27, 2023収支内訳Chugai Pharmaceutical の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:CHGC.Y 収益、費用、利益 ( )JPY Millions日付収益収益G+A経費研究開発費30 Jun 261,342,808471,372122,758190,64931 Mar 261,291,229452,196122,125188,55831 Dec 251,257,941434,012116,461187,59830 Sep 251,213,713397,161111,954187,42030 Jun 251,196,214395,444111,845183,73931 Mar 251,222,121410,150110,749181,01231 Dec 241,170,611387,317110,098181,44030 Sep 241,142,350386,964108,439171,06830 Jun 241,084,570355,041108,201171,72231 Mar 241,036,076326,373114,150173,35631 Dec 231,111,367325,472112,580174,86830 Sep 231,276,051336,745112,702178,24430 Jun 231,243,437326,969107,753169,37931 Mar 231,211,632316,15496,519158,62731 Dec 221,259,946374,429100,760149,62630 Sep 221,143,716370,791104,720142,20130 Jun 221,205,696389,011106,839141,69531 Mar 221,191,496387,359107,887141,43831 Dec 21999,759302,995102,416137,29930 Sep 21887,919256,46298,992132,32430 Jun 21809,055230,57796,489126,26531 Mar 21776,339210,61194,546121,47731 Dec 20786,946214,73394,401117,85030 Sep 20753,853202,59095,497116,04930 Jun 20734,019190,59996,919110,99431 Mar 20711,320174,062102,068108,90331 Dec 19686,184157,560101,574107,94230 Sep 19662,198139,54399,844105,23130 Jun 19614,949113,07097,895102,49131 Mar 19586,64899,63192,37999,28931 Dec 18579,78792,48893,41699,20230 Sep 18572,99485,85791,55398,15030 Jun 18566,54885,28589,71096,63931 Mar 18556,15982,10189,63198,74431 Dec 17534,19972,71388,14792,94730 Sep 17517,90867,70482,41190,42730 Jun 17497,02358,14382,46589,72831 Mar 17497,35457,59281,24885,00031 Dec 16491,78053,59281,94185,01130 Sep 16492,58456,56285,48183,36630 Jun 16506,19262,53786,31384,76131 Mar 16501,64961,04387,77284,11131 Dec 15498,83961,12588,01883,79930 Sep 15495,45558,89785,49285,815質の高い収益: CHGC.Yは 高品質の収益 を持っています。利益率の向上: CHGC.Yの現在の純利益率 (35.1%)は、昨年(33.1%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: CHGC.Yの収益は過去 5 年間で年間8.3%増加しました。成長の加速: CHGC.Yの過去 1 年間の収益成長率 ( 19.2% ) は、5 年間の平均 ( 年間8.3%を上回っています。収益対業界: CHGC.Yの過去 1 年間の収益成長率 ( 19.2% ) はPharmaceuticals業界-6%を上回りました。株主資本利益率高いROE: CHGC.Yの 自己資本利益率 ( 23.2% ) は 高い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/31 23:51終値2026/07/31 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Chugai Pharmaceutical Co., Ltd. 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。27 アナリスト機関Atsushi SekiBarclaysMiki SogiBernsteinKoichi MameganoBofA Global Research24 その他のアナリストを表示
お知らせ • Oct 27+ 3 more updatesChugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Jan 29, 2026Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Jan 29, 2026
お知らせ • Oct 18+ 3 more updatesChugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Jan 30, 2025Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results at 5:00 PM, Tokyo Standard Time on Jan 30, 2025
お知らせ • Dec 07+ 2 more updatesChugai Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024Chugai Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results at 5:00 PM, Tokyo Standard Time on Oct 25, 2024
お知らせ • Dec 06Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Feb 01, 2024Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2023 results at 5:00 PM, Tokyo Standard Time on Feb 01, 2024
お知らせ • Nov 01Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on Feb 02, 2023Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2022 results at 5:00 PM, Tokyo Standard Time on Feb 02, 2023
お知らせ • Oct 28+ 2 more updatesChugai Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Apr 27, 2023Chugai Pharmaceutical Co., Ltd. announced that they will report Q1, 2023 results on Apr 27, 2023
お知らせ • 5hChugai Pharmaceutical Files For Additional Indication Of Enspryng For Prevention Of Relapse In MOG Antibody-Associated Disease In JapanChugai Pharmaceutical Co., Ltd. filed a regulatory application with the Ministry of Health, Labour and Welfare for an additional indication of 'prevention of relapse in MOG antibody-associated disease' for Enspryng [generic name: satralizumab (genetical recombination)], a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody created by Chugai. Enspryng received forerunner designation in 2023 as a treatment for the disease. If approved, Enspryng would become the first treatment covered by health insurance in Japan for the disease. This filing is based on results from METEOROID, a global phase III clinical study in adults and adolescents (aged 12-17 years) with MOGAD. Development in Japan is conducted by Chugai, and Japanese patients have participated in this study. Enspryng, created by Chugai, is a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody, which was the first product developed by applying Chugai's proprietary recycling antibody technology. Recycling antibody technology received 'The Imperial Invention Prize,' the highest honor of the Fiscal Year 2026 National Commendation for Invention. Enspryng is approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in approximately 90 countries, including Japan, the United States, and Europe. A global phase III clinical study is currently ongoing in autoimmune encephalitis (AIE). In addition, the U.S. Food and Drug Administration (FDA) has accepted the filing for thyroid eye disease (TED) and granted priority review. MOG antibody-associated disease (myelin oligodendrocyte glycoprotein antibody-associated disease, MOGAD) is an autoimmune disease involving demyelination by which a pathogenic autoantibody, an anti-MOG antibody, binds to MOG, which is expressed on the surface of the myelin sheath in the central nervous system. MOGAD causes inflammation of the optic nerves, spinal cord and brain, with symptoms such as visual impairment, loss of sensation, motor dysfunction and dysuria. Currently, no approved therapies exist for the prevention of relapse in MOGAD, and in about 80% of adult patients, the disease is chronic and characterized by a relapsing course with currently used therapies. The inflammatory cytokine IL-6 may play a role in the pathogenesis of MOGAD by promoting the production of autoantibodies and inducing inflammatory effects. The number of patients in Japan is estimated to be approximately 1,700.
お知らせ • Mar 23Chugai Pharmaceutical Co., Ltd. Announces Discontinuation Of Development Of GYM329 (Emugrobart) In Spinal Muscular Atrophy And Facioscapulohumeral Muscular DystrophyChugai Pharmaceutical Co., Ltd. announced that Roche has decided to discontinue the clinical development of GYM329 (emugrobart), an investigational anti-latent myostatin sweeping antibody, for spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD). This decision follows a rigorous assessment of data from the Phase II/III MANATEE study (Part 1) in SMA and the Phase II MANOEUVRE study in FSHD. While emugrobart showed a favorable safety profile and target engagement by reducing mature myostatin, it did not translate into the intended functional outcomes. Specifically, muscle growth and exploratory functional efficacy were neither consistent nor robust enough across study participants to provide sufficient confidence for Phase III development in SMA and FSHD. Emugrobart was well tolerated across both studies, with no serious adverse events or treatment withdrawals. The discontinuation of these studies was not due to safety concerns. As the scientific rationale for continuing to investigate emugrobart in obesity remains strong, this decision does not impact the development of emugrobart in obesity. Obesity is a chronic metabolic disease with symptoms and underlying causes being fundamentally different from neuromuscular conditions like SMA and FSHD. In obesity, muscle quality is not primarily affected by a neurodegenerative (nerve-wasting) or myopathic (muscle-wasting) process and there is generally more myostatin for an anti-myostatin antibody to act on. Consequently, the Phase II development of emugrobart in obesity will continue as planned.
お知らせ • Feb 24Sarepta Therapeutics, Inc. Announces Commercial Launch of ELEVIDYS in JapanSarepta Therapeutics, Inc. announced the commercial launch of ELEVIDYS (delandistrogene moxeparvovec) in Japan by Chugai Pharmaceutical Co. Ltd., following its reimbursement listing on Japan's National Health Insurance (NHI) price list. ELEVIDYS is the first gene therapy to be launched in Japan for Duchenne muscular dystrophy (DMD). In Japan, ELEVIDYS is available for ambulatory individuals with Duchenne ages 3-to less than 8-years-old, a deletion of any portion or the entirety of exon 8 and/or exon 9 in the DMD gene, and who are negative for anti-AAVrh74 antibodies. Chugai announced that ELEVIDYS has been launched in Japan following reimbursement listing, enabling access for eligible patients under the conditional and time limited approval granted by Japan's Ministry of Health, Labour and Welfare (MHLW) in May 2025. Chugai will be responsible for postmarketing clinical studies and all case postmarketing surveillance in Japan as part of the Roche Group collaboration to further evaluate long-term efficacy and safety. The approval in Japan was based on efficacy and safety data from the ELEVIDYS clinical development program, including results from the global Phase 3 EMBARK study. EMBARK evaluated ELEVIDYS in ambulatory boys with DMD and demonstrated clinically meaningful improvements in key motor function measures. ADVERSE REACTIONS: The most common adverse reactions (incidence 5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, thrombocytopenia, and troponin-I increased. Report negative side effects of prescription drugs to the FDA.
お知らせ • Jan 29+ 3 more updatesChugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026.
お知らせ • Oct 27+ 3 more updatesChugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Jan 29, 2026Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Jan 29, 2026
お知らせ • Oct 25Chugai Pharmaceutical Co., Ltd. (TSE:4519) agreed to acquire Renalys Pharma for ¥31 billion.Chugai Pharmaceutical Co., Ltd. (TSE:4519) agreed to acquire Renalys Pharma for ¥31 billion on October 24, 2025. A cash consideration of ¥15 billion will be paid by Chugai Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd. will pay an earnout/contingent payment of ¥16 billion cash. As part of consideration, ¥31 billion is paid towards common equity of Renalys Pharma. The expected completion of the transaction is November 30, 2025.
お知らせ • Feb 01Chugai Pharmaceutical Co., Ltd. Provides Guidance for the Financial Year Ending December 31, 2025Chugai Pharmaceutical Co., Ltd. provided consolidated non-audited earnings guidance for the financial year ending December 31, 2025. For the year, company expects revenues of JPY 1,190,000 million, Core operating profit of JPY 570,000 million, Core net income of JPY 410,000 million and Core earnings per share of JPY 250.00.
お知らせ • Jan 31Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2025Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2025.
お知らせ • Jan 16CHEPLAPHARM K.K. agreed to acquire the Japan business concerning the anti-cancer agent Tarceva® Tablets 25, 100, and 150 from Chugai Pharmaceutical Co., Ltd. (TSE:4519).CHEPLAPHARM K.K. agreed to acquire the Japan business concerning the anti-cancer agent Tarceva® Tablets 25, 100, and 150 from Chugai Pharmaceutical Co., Ltd. (TSE:4519) on January 14, 2025. Upon completion, CHEPLAPHARM group will solely market Tarceva after transferring assets related to Tarceva that are owned by Roche Group and Chugai Pharmaceutical Co., Ltd. (TSE:4519), including the marketing authorization and intellectual property rights (patents and trademarks, etc.). The transfer of the marketing authorization is scheduled to take place on April 1, 2025, and the sales transfer is scheduled to take place in June 2025.
お知らせ • Oct 18+ 3 more updatesChugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Jan 30, 2025Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results at 5:00 PM, Tokyo Standard Time on Jan 30, 2025
お知らせ • Feb 01+ 1 more updateChugai Pharmaceutical Co., Ltd. Provides Consolidated Non-Audited Earnings Guidance for the Financial Year 2024Chugai Pharmaceutical Co., Ltd. provided consolidated non-audited earnings guidance for the financial year 2024. For the year, company expects revenues of JPY 1,070,000 million, Core operating profit of JPY 460,000 million, Core net income of JPY 335,500 million and Core earnings per share of JPY 204.00.
お知らせ • Dec 07+ 2 more updatesChugai Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024Chugai Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results at 5:00 PM, Tokyo Standard Time on Oct 25, 2024
お知らせ • Dec 06Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Feb 01, 2024Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2023 results at 5:00 PM, Tokyo Standard Time on Feb 01, 2024
お知らせ • Oct 26+ 1 more updateChugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Nine Months and Financial Year Ending December 31, 2023Chugai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the first nine months and financial year ending December 31, 2023. For the first nine months, the company expects core revenues of ¥837,555 million, Core operating profit of ¥340,537 million, Core net income of ¥250,298 million and Core earnings per share of ¥152.11.For the year, company expects core revenues of ¥1,070,000 million, Core operating profit of ¥415,000 million, Core net income of ¥306,000 million and Core earnings per share of ¥186.00.
お知らせ • Feb 03Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Financial Year 2023Chugai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the financial year 2023. For the year, company expects revenues of ¥1,070,000 million, Core operating profit of ¥415,000 million, Core net income of ¥306,000 million and Core earnings per share of ¥186.00.
お知らせ • Feb 02+ 1 more updateChugai Pharmaceutical Co., Ltd. Approves Dividend Fiscal Year Ended December 31, 2022, Effective March 31, 2023Chugai Pharmaceutical Co., Ltd. at its board meeting held on February 2, 2023 approved to distribute retained earnings with the record date being December 31, 2022 for the fiscal year ended December 31, 2022. Dividends per share is JPY 40.00. Total dividends are JPY 65,801 million. Effective date is March 31, 2023.
お知らせ • Nov 01Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on Feb 02, 2023Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2022 results at 5:00 PM, Tokyo Standard Time on Feb 02, 2023
お知らせ • Oct 28+ 2 more updatesChugai Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Apr 27, 2023Chugai Pharmaceutical Co., Ltd. announced that they will report Q1, 2023 results on Apr 27, 2023